[18F] Fluoromisonidazole and [18F] Fluorodeoxyglucose PET in Lung Cancer Treatment Response
Author Information
Author(s): Gagel Bernd, Reinartz Patrick, Demirel Cengiz, Kaiser Hans J, Zimny Michael, Piroth Marc, Pinkawa Michael, Stanzel Sven, Asadpour Branka, Hamacher Kurt, Coenen Heinz H, Buell Ulrich, Eble Michael J
Primary Institution: University of Aachen, Germany
Hypothesis
The study aims to show the feasibility of determining hypoxia and early tumor response using FMISO and FDG PET after chemotherapy and radiotherapy in non-small-cell lung cancer.
Conclusion
The preliminary results suggest that FMISO and FDG PET can help evaluate treatment effectiveness and predict patient outcomes in lung cancer.
Supporting Evidence
- FMISO PET allowed for the qualitative and quantitative definition of hypoxic sub-areas.
- Changes in FMISO and FDG PET measure the early response to therapy.
- All five patients with decreased FDG uptake had a partial remission after chemotherapy.
- Three patients had a complete remission after radio-/chemotherapy.
- Discrepancies were noted between FDG PET and CT response in some patients.
Takeaway
Doctors used special scans to see how well lung cancer treatment was working, and they found that these scans could help predict if patients would get better.
Methodology
Eight patients with non-small-cell lung cancer underwent FMISO and FDG PET scans before and after chemotherapy to measure tumor hypoxia and glucose metabolism.
Limitations
The study included only a small number of patients, and the results need validation in larger trials.
Participant Demographics
{"mean_age":58,"sex_distribution":{"male":5,"female":3},"clinical_stage":{"IIIA":1,"IIIB":6,"IV":1}}
Statistical Information
P-Value
0.033
Statistical Significance
p = 0.033
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website